Clinical Trial Update: MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL [Phase 2]

View source ↗

Summary

Phase 2 trial of MZL-IPI risk-adapted targeted therapy for untreated marginal zone lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• MZL-IPI

Snippet

Sponsor: Ruijin Hospital | Conditions: Marginal Zone Lymphoma(MZL) | Phase 2 | Status: RECRUITING